Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 5/5/12  and contains information from public web pages.

Dr. Nicholas Robert

Wrong Dr. Nicholas Robert?
 
Background

Employment History

Board Memberships and Affiliations

Education

  • MD
18 Total References
Web References
"This study shows that the addition ...
www.breastcancerweek.org, 5 May 2012 [cached]
"This study shows that the addition of carboplatin may provide clinical benefit and demonstrates improvement in response rate and time to disease progression in HER2-positive metastatic breast cancer patients," said Dr. Nicholas Robert of Inova Fairfax Hospital in Virginia and lead investigator. "In addition, the preliminary analysis of survival is encouraging."
Meet Our Team - Inova Health System
www.inova.org, 27 Mar 2010 [cached]
Nicholas Robert, MD
Genentech: Press Releases - News Release Wednesday, Dec 11, 2002
www.genentech.com, 11 Dec 2002 [cached]
Results of this trial were presented at the San Antonio Breast Cancer Symposium by lead investigator Nicholas Robert, M.D., of Inova Fairfax Hospital, Fairfax, Virginia.
"This study shows that the addition of carboplatin may provide clinical benefit and demonstrates improvement in response rate and time to disease progression in HER2-positive metastatic breast cancer patients," said Dr. Robert."In addition, the preliminary analysis of survival is encouraging."Median survival in the Herceptin and paclitaxel arm was 33.5 months and has not been reached at 36 months of follow-up in the Herceptin, paclitaxel and carboplatin arm.
The study (abstract # 35) enrolled 194 women who had evidence of HER2 protein overexpression by immunohistochemistry (IHC); 191 patients wereevaluable for the primary endpoint of time to progression.Results of the randomized study showed that women receiving Herceptin, paclitaxel and carboplatin had a median time to progression of 11.2 months, compared to 6.9 months for those receiving standard treatment of Herceptin and paclitaxel alone.In women with IHC scores of 3+, those treated with all three agents had a median time to progression of 13.5 months, compared to 7.2 months in the group receiving Herceptin and paclitaxel.Investigators are in the process of retrospectively testing tumor samples in this study by FISH (fluorescence in-situ hybridization), a gene-based HER2 diagnostic test.
Inova Fairfax Hospital Honored For Outstanding Cancer Treatment | Inova Newsroom
inova.tekgroup.com, 28 July 2008 [cached]
"Part of providing quality cancer care is looking at the full scope of options available to the patient, including education, research, outreach and the most current data regarding cancer treatment," said Nicholas Robert, MD, Inova Fairfax Hospital cancer committee chairman.
Principal Investigator: Nicholas ...
www.inova.org, 1 Dec 2011 [cached]
Principal Investigator: Nicholas Robert, MD
...
Principal Investigator: Nicholas Robert, MD
...
Principal Investigator: Nicholas Robert, MD
...
Principal Investigator: Nicholas Robert, MD
...
Principal Investigator: Nicholas Robert, MD
...
Principal Investigator: Nicholas Robert, MD
Other People with the name "Robert":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304